Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 5, 1997, Pages 387-396

  Bhatti, M Masood ^b   Foster, Robert T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

Bioavailability; Pharmacokinetics; Rat; Verapamil enantiomers

Indexed keywords

CALCIUM ANTAGONIST; VERAPAMIL;

ARTICLE; CALCIUM ANTAGONISM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RACEMIC MIXTURE; RAT; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; VERAPAMIL;

EID: 0030877664     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199707)18:5<387::AID-BDD26>3.0.CO;2-X     Document Type: Article

References (27)

1. K. K. Hla, J. A. Henry and L. N. Latham, Pharmacokinetic and pharmacodynamic of two formulations of verapamil. Br. J. Clin. Pharmacol., 24, 661-664 (1987).
2. Y. W. Kwon and J. T. David, Clinical aspects of drug action at ion channels: a commentary on the stereoselectivity of drug actions at voltage-gated ion channels. Chirality, 3, 393-404 (1991).
3. K. Satoh, T. Yanagisawa and T. Taira, Coronary vasodilator and cardiac effects of optical isomers of verapamil in the dog. J. Cardiovasc. Pharmacol., 2, 309-318 (1980).
4. J. C. Giacommi, W. L. Nelson, L. Theodore, F. M. Wong, D. Rood and K. M. Giacomini, The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. J. Cardiovasc. Pharmacol., 7, 469-475 (1985).
5. S. R. Humann, R. A. Blouin and R. G. McAllister, Jr., Clinical pharmacokinetics of verapamil. Clin. Pharmacokinet., 9, 26-41 (1984).
6. H. M. McIlhenny, Metabolism of [14C] verapamil. J. Med. Chem., 14, 1178-1184 (1971).
7. R. G. McAllister, Jr., D. W. A. Bourne and L. W. Dittert, The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the electrocardiogram. J. Pharmacol. Exp. Ther., 202, 38-44 (1977).
8. E. L. Todd and D. R. Abernethy, Physiological pharmacokinetics and pharmacodynamics of (+/-) verapamil in female rats. Biopharm. Drug Disposit., 8, 285-297 (1987).
9. P. Manitpisitkul and W. L. Chiou, Intravenous verapamil kinetics in rats; marked arteriovenous concentration and comparison with human. Biopharm. Drug Disposit., 14, 555-566 (1993).
10. S. A. Bai, M. Lankford and L. M. Johnson, Pharmacokinetics of the enantiomers of verapamil in the dog. Chirality 5, 436-442 (1993).
11. F. H. Hsu, T. Prueksaritanont, M. G. Lee and W. L. Chiou, The phenomenon and cause of the dose-dependent oral absorption of chlorothiazole in rats. J. Pharmacokinet. Biopharm., 15, 369-383 (1987).
12. W. L. Chiou, T. M. Chen, Y. S. Choo and M. H. Abdel-Hameed, Alternative derivation for the gastrointestinal absorption residence time. J. Pharm. Sci., 81, 486-487 (1992).
13. J. Mordenti, Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci., 75, 1028-1040 (1986).
14. H. Boxenbaum, Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance; extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm., 8, 165-176 (1980).
15. F. H. Hsu and W. L. Chiou, Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharm. Res., 5, S-211 (1988).
16. W. L. Nelson, E. D. Olsen, D. B. Beitner and R. J. Pallow, Jr., Reiochemistry and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver. Drug Metab. Disposit., 16, 184-188 (1988).
17. R. Mehvar, J. M. Reynolds, M. A. Robinson and J. A. Longstreth, Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers. J. Pharm. Sci., 11, 1815-1819 (1994).
18. M. M. Bhatti, F. M. Pasutto and R. T. Foster, Stereospecific high-performance liquid chromatographic assay of verapamil and norverapamil in human plasma using a chiral stationary phase. Pharm. Res., 11, S22 (1994).
19. M. L. Rocci and W. J. Jusko, Lagran program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed., 16, 203-216 (1983).
20. M. Eichelbaum, G. Mikus and B. Vogelgesang, Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br. J. Clin. Pharmacol., 17, 453-158 (1984).
21. M. M. Bhatti, R. Z. Lewanczuk, F. M. Pasutto and R. T. Foster, Pharmacokmetics of verapamil and norverapamil enantiomers following administration of immediate and controlled-release formulations to humans: evidence suggesting input-rate determined stereoselectivity. J. Clin. Pharmacol., 35, 1076-1082 (1995).
22. R. L. Koch and P. Palicharla, The anaerobic metabolism of verapamil in rat cecal contents forms norverapamil and thiocyanate. J. Pharmacol. Exp. Ther., 254, 612-615 (1990).
23. G. Mikus, M. Eichelbaum, C. Fischer, S. Gumulka and U. Klotz, Interaction of verapamil and cimetidine: stereochemical drug metabolism, drug disposition and drug action. J. Pharmacol. Exp. Ther., 253, 1042-1048 (1990).
24. J. R. Gillette, Factor effecting drug metabolism. Ann. N.Y. Acad. Sci., 179, 43-66 (1971).
25. M. M. Bhatti, R. Z. Lewanczuk and R. T. Foster, Protein binding of verapamil and norverapamil enantiomers in young and elderly human and rat serum using ultrafiltration. Pharm. Res., 12, S337 (1995).
26. M. E. Laethem, F. M. Belpaire, P. Wijnant, M. Rosseel and M. G. Bogaert, Influence of endotoxin on the stereoselective pharmacokinetics of oxyprenolol, propranolol and verapamil in the rat. Chirality, 6, 405-410 (1994).
27. A. S. Gross, B. Heuer and M. Eichelbaum, Stereoselective protein binding of verapamil enantiomers. Biochem. Pharmacol., 37, 4623-4627 (1988).